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Effects of curcumin analogue, 2, 6-bis (2, 5-dimethoxybenzylidene) cyclohexanone 
(BDMC33) on the activities of drug-metabolizing enzymes in cultured Caco-2 cell model 
ABSTRACT 
Poor systemic delivery of curcumin outside the gut due to its rapid metabolism has severely 
limited its application to many chronic diseases. Previously, our research group synthesized 
curcumin analogues 2, 6-bis (2, 5-dimethoxybenzylidene) cyclohexanone (BDMC33) that has 
potent anti-inflammatory activities. Therefore, the aim of this study is to evaluate the effects 
of curcumin analog (BDMC33) on the activities of drug metabolizing enzymes in Caco-2 
cells, which was compared with that of curcumin and 3-(2-Fluoro-benzylidene)-5-(2-
fluorocyclohexylmethylene)-piperidin-4-one (EF-24). BDMC-33 was synthesized through 
the appropriate reaction of the aromatic aldehyde with cyclohexanone, under base catalyzed 
aldol condensation, at the ratio of ketone: aldehyde (1:2). Activity of drug metabolizing 
enzymes such as NADPH-cytochrome p450 reductase (CPR), UDP-glucuronosyltransferase 
(UGT), glutathione-S-transferase (GST) and Sulfotransferase (SULT) in Caco-2 cells were 
evaluated upon exposure to 50µM of BDMC33, curcumin, and EF-24, separately, for 4 
hours. The BDMC33, EF-24, and curcumin treatments did not affect the activities of UGT, 
GST, SULT, and CPR in respect to their controls (29.45, 27.18, 23.64 and 2.08µmol/mg), 
respectively, at all periods of incubation. Hence, BDMC33 was able to maintain the activities 
of both phases I and II drug metabolizing enzymes, and therefore it could be a potential lead, 
anti-inflammatory agents. 
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